Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Thomas Budd

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
The American Journal of Surgical Pathology|August 26, 2006
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks, Sarah M Short, Nichole L Prescott, et al.
Neuro-Oncology|February 7, 2019
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasisJoseph M Kim, Jacob A Miller, Rupesh Kotecha, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.
Plos Medicine|August 2, 2021
Cardiac risk stratification in cancer patients: A longitudinal patient-patient network analysisYuan Hou, Yadi Zhou, Muzna Hussain, et al.
Open Heart|November 27, 2020
Impact of timing of atrial fibrillation, CHA<sub>2</sub>DS<sub>2</sub>-VASc score and cancer therapeutics on mortality in oncology patientsMuzna Hussain, Rabel Misbah, Eoin Donnellan, et al.
Technology in Cancer Research & Treatment|September 29, 2022
A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study ProtocolAnukriti Sharma, Ken B Johnson, Bihua Bie, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
The American Journal of Surgical Pathology|August 26, 2006
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks, Sarah M Short, Nichole L Prescott, et al.
Neuro-Oncology|February 7, 2019
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasisJoseph M Kim, Jacob A Miller, Rupesh Kotecha, et al.
Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.
Plos Medicine|August 2, 2021
Cardiac risk stratification in cancer patients: A longitudinal patient-patient network analysisYuan Hou, Yadi Zhou, Muzna Hussain, et al.
Open Heart|November 27, 2020
Impact of timing of atrial fibrillation, CHA<sub>2</sub>DS<sub>2</sub>-VASc score and cancer therapeutics on mortality in oncology patientsMuzna Hussain, Rabel Misbah, Eoin Donnellan, et al.
Technology in Cancer Research & Treatment|September 29, 2022
A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study ProtocolAnukriti Sharma, Ken B Johnson, Bihua Bie, et al.
BMC Cancer|March 24, 2010
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrenceDavid G Hicks, Bagi R Janarthanan, Ramya Vardarajan, et al.
Pageof 11